Knee Replacement Implant Names & Brands Available in India
CDSCO-registered knee replacement implant brands and systems sold in India, how NPPA caps their price, and what a hospital pharmacy needs to know.
This piece runs through the real knee replacement names, brands and implant categories registered for sale in India, explains how the NPPA ceiling price works across all of them, and closes on why a hospital's own pharmacy and implant-stocking discipline determines whether that surgery revenue stays in-house.
What implant brands are actually registered for sale in India?
The knee replacement names a hospital procurement team encounters most often are Stryker India (Total Knee Replacement System-Scorpio), DePuy Medical (PFC Sigma RPF Knee System), B. Braun Medical India, and Exactech India, alongside Zimmer Biomet and Smith+Nephew products sold through their Indian subsidiaries, all listed on CDSCO's medical device registration records.
Domestic manufacturers hold a real share too. Smit MediMed, established in 1990, and Uteshiya Medicare both carry CDSCO manufacturing licences for sterile orthopaedic implants, including knee systems, and compete on price against the imported brands within the same NPPA ceiling. A hospital comparing knee replacement names for procurement should treat CDSCO registration, not company size, as the baseline eligibility filter.
What types of knee implant systems exist under these brand names?
Regardless of manufacturer, every registered system falls into the same functional categories: primary total knee replacement (with or without patellar resurfacing), unicondylar (partial) knee systems, and revision knee systems for repeat surgery after implant failure or loosening. NPPA's own price notification itemises ceiling prices separately by these categories, not by brand.
A hospital pharmacy or procurement desk doesn't need to track dozens of brand names individually; it needs to track which of these functional categories it stocks or has on consignment, since that is what determines both the ceiling price that applies and what a surgeon will actually request during a case.
How does the government cap the price across every brand?
NPPA first fixed ceiling prices for orthopaedic knee implants on 16 August 2017, invoking its special powers under Paragraph 19 of the Drugs (Prices Control) Order, 2013, after finding what it called unjustified trade margins driving up costs. The intervention cut prices by as much as 69%, producing an estimated national saving of ₹1,500 crore a year for patients.
That ceiling has been extended annually since, most recently through further NPPA notifications, and applies uniformly across every registered brand: a Stryker system and a domestic Indian system for the same functional category sit under the same rupee ceiling, with the manufacturer setting its actual price at or below that cap rather than above it.
Why does the price ceiling apply the same way to every brand name?
The ceiling price is fixed per functional category of implant (primary with patella, primary without patella, revision femoral, revision tibial, and so on), not per company, which means the brand name on the implant tray has no bearing on the regulatory price cap itself. A hospital cannot legally be charged above the notified ceiling for a given category regardless of which registered manufacturer supplied it.
This matters for procurement because it removes brand premium as a legitimate reason for price variation within a category; where prices do vary between brands, it reflects the manufacturer's own pricing decision within the ceiling, not a different regulatory tier.
How do implant categories compare on typical price ceiling?
Ceiling prices differ sharply by category, not by brand name. The table below sets out where the 2024 NPPA notification placed each functional category, useful when comparing knee replacement names against what a hospital should actually expect to pay.
| Implant category | 2024 NPPA ceiling price (approx., per unit) | Registered brand examples |
|---|---|---|
| Primary knee replacement system, with patella | ₹5,443.79 (lower end of range) | Stryker, DePuy, Zimmer Biomet, Smith+Nephew, domestic makers |
| Primary knee replacement system, without patella | Set separately under the same notification | Same manufacturer base |
| Revision knee replacement system, femoral component | Up to ₹83,546.87 (higher end of range) | Global majors primarily; fewer domestic revision systems |
Figures are from NPPA's 2024 ceiling price notification for orthopaedic knee implants and change with each annual revision. A hospital should always confirm the current notified ceiling before finalising a procurement rate, since the number attached to any of these knee replacement names shifts every review cycle.
Why does implant and drug availability matter to a hospital's own pharmacy?
A total knee replacement doesn't end in the operating theatre. The patient leaves with a prescription for analgesics, anticoagulant prophylaxis and, often, a short antibiotic course, and every one of those prescriptions either gets filled inside the hospital or walks to the nearest outside chemist.
A hospital that runs joint-replacement volume without a reliable in-house pharmacy for this post-operative drug set is giving away exactly the continuity-of-care revenue the surgery itself should anchor. The implant brand on the tray earns the hospital nothing extra if the follow-up prescription leaves with the patient. Medyzen's managed hospital pharmacy model is built for this handoff between a high-value procedure and the routine drug stocking that follows it. The broader cost of letting that prescription leave the building is covered in prescription leakage and hospital revenue loss, and the stocking economics behind branded-versus-generic post-operative drugs are covered in branded vs generic medicine margins.
Sources
- 1Notification regarding ceiling price fixation/revision of Orthopaedic Knee Implants for Knee Replacement System — National Pharmaceutical Pricing Authority
- 2Government fixes ceiling prices of Knee Implants; People of India to save Rs.1500 crore per annum — Press Information Bureau, Government of India
- 3NPPA extends ceiling prices of Knee Implants — Press Information Bureau, Government of India
- 4Central Drugs Standard Control Organisation — Medical Devices — Government of India
- 5The ceiling price of orthopaedic knee implants to be monitored such that the price increase does not exceed 10% in a given year — Press Information Bureau, Government of India
This article is for informational purposes and is not a substitute for professional medical advice. Implant selection is a clinical decision made by the treating orthopaedic surgeon based on the individual patient. Prices cited are NPPA ceiling prices as of the most recent notification and are revised periodically; confirm the current notified ceiling before procurement.
FAQ
Frequently asked questions
CDSCO-registered manufacturers include Stryker India, DePuy Medical (Johnson & Johnson), Zimmer Biomet, Smith+Nephew, B. Braun Medical India, Exactech India, and domestic makers including Smit MediMed and Uteshiya Medicare.
No single brand carries a fixed uniform price, but every brand's price for a given implant category must sit at or below the NPPA-notified ceiling for that category, regardless of manufacturer.
NPPA found unjustified trade margins were pushing implant prices to levels that discouraged patients from getting needed surgery, and used its emergency powers under Paragraph 19 of the DPCO 2013 to fix ceiling prices in August 2017.
Domestic manufacturers registered with CDSCO must meet the same regulatory quality and safety requirements as multinational manufacturers to sell in India; the clinical choice between specific systems is a surgeon's decision based on case-specific factors, not a regulatory distinction.
No. The NPPA ceiling applies only to the implant device itself, not to surgeon fees, hospital stay, operating theatre charges or rehabilitation, which are priced separately by the treating hospital.
Dr. Anurag SharmaMBBS, M.S. Orthopaedics
Consultant Orthopaedic Surgeon
Dr. Anurag Sharma is a Consultant Orthopaedic Surgeon specializing in Joint Replacement & Preservation and Sports Injury & Arthroscopy. He holds an M.S. in Orthopaedics from S.M.S. Medical College, Jaipur, a fellowship in Joint Replacement and Pelvi-acetabular Surgeries under Dr. Ramesh Sen, and an Executive Program in Public Health Policy, Leadership and Management from AIIMS Jodhpur.